?This report highlights why Grace Century?s portfolio projects are 100% in healthcare and life sciences,? explains Scott Wolf, CEO of Grace Century. “The sector (life sciences) is not only where the future of healthcare is, but it has also proven to be immune from economic cycles such as recession, and volatility in financial markets.”
VENTURE CAPITAL DOLLARS INVESTED IN LIFE SCIENCES COMPANIES IN 2014 AT HIGHEST LEVEL SINCE 2007, ACCORDING TO THE MONEYTREE REPORT
Venture Capitalists Invested $2.8 Billion in Life Sciences in the Fourth Quarter, Reaching $8.6 Billion in 2014. Biotechnology Industry Reached Record-Level of Investment during the Fourth Quarter.
NEW YORK, February 12, 2015 ? Venture capital (VC) funding for the Life Sciences sector ? Biotechnology and Medical Devices ? increased 49 percent in dollars but declined 18 percent in deals during the fourth quarter of 2014, compared to fourth quarter of 2013, according to theMoneyTree? Report from PricewaterhouseCoopers (PwC) LLP and the National Venture Capital Association (NVCA), based on data provided by Thomson Reuters. The report, entitled ?Biotech funding surges,? shows that VCs invested $2.8 billion in 202 Life Sciences deals during the quarter, versus $1.9 billion going into 245 deals in the fourth quarter of 2013 and $1.7 billion in 197 deals during the previous quarter in 2014.